Mode
Text Size
Log in / Sign up
Phase 3 N=330 Randomized Quadruple-blind Treatment

Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial

Amyotrophic Lateral Sclerosis

Enrolled (actual)
330
Serious AEs
9.1%
Results posted
Feb 2013
Primary outcome: Primary: Rate of Change in Composite Manual Muscle Testing (MMT) Score — 0.44; 0.39 MMT units per month — p=0.529

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Insulin like growth factor, type 1 (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Mayo Clinic
Primary completion
Aug 2007

Outcome Measures

OutcomeResultp-value
PRIMARY
Rate of Change in Composite Manual Muscle Testing (MMT) Score
0.44; 0.39 0.529
SECONDARY
Number of Participants Alive and Tracheostomy-free at 24 Months
93; 90 0.415
SECONDARY
Rate of Change in ALS Functional Rating Scale.
2.5; 2.2 0.321

Summary

The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients. Study participants will be followed for 2 years once enrolled. They will receive either placebo or the active IGF-I. Examinations will take place at approximately 6-month intervals.

Eligibility Criteria

Inclusion Criteria

Patients entering this study:

  • Are between the ages of 18-80 years old.
  • Legal residents of the United States or Canada.
  • Have a history of a chronic onset of a progressive motor weakness of less than 24 months duration.
  • Fulfill El Escorial criteria of probable or definite ALS.
  • If female, are surgically sterile, two years postmenopausal, or if of child-bearing potential, must be using a medically acceptable method of birth control and agree to continue use of this method for the duration of the study. Acceptable methods include a barrier method with spermicide, oral contraceptives (normal doses are acceptable; low dose oral contraceptives or contraceptive implants must be used with a barrier method), intrauterine device (IUD), or abstinence. Have a negative pregnancy test.
  • Are able to comply with protocol requirements.
  • Can provide written informed consent.
  • Have a manual muscle testing score of less than 8.
  • Have a forced vital capacity by pulmonary function testing *60% predicted.

Exclusion Criteria

Patients entering this study will not:

  • Have any of the following conditions: renal disease (Creatine > 2.0) or other active systemic disease
  • Have any clinically significant abnormalities on the prestudy laboratory evaluation, physical examination, ECG, chest x-ray or ophthalmologic exam.
  • Have any clinically significant medical condition (e.g., within six months of baseline, had myocardial infarction, angina pectoris, and/or congestive heart failure) that, in the opinion of the investigator, would compromise the safety of patient.
  • Have Type I or Type II diabetes.
  • Have a history of cancer including melanoma with the exception of localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of baseline) and carcinoma in-situ of the cervix (women only).
  • Have used an investigational drug within 30 days of baseline visit.
  • Have had a tracheostomy.
  • Have a Beck's Depression Inventory score * 12.
  • Have legal residency outside of the United States or Canada.
  • Be pregnant or breast-feeding.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00035815). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search